EIKN (EIKN) Competitors $10.91 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$10.91 0.00 (0.00%) As of 05/22/2026 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock EIKN vs. RARE, KLRA, IMNM, NBTX, and MLYSShould you buy EIKN stock or one of its competitors? MarketBeat compares EIKN with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with EIKN include Ultragenyx Pharmaceutical (RARE), Kailera Therapeutics (KLRA), Immunome (IMNM), Nanobiotix (NBTX), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. EIKN vs. RAREEIKN vs. KLRAEIKN vs. IMNMEIKN vs. NBTXEIKN vs. MLYSHow does EIKN compare to Ultragenyx Pharmaceutical?Ultragenyx Pharmaceutical (NASDAQ:RARE) and EIKN (NASDAQ:EIKN) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment. Do analysts recommend RARE or EIKN? Ultragenyx Pharmaceutical currently has a consensus price target of $59.88, indicating a potential upside of 156.02%. EIKN has a consensus price target of $25.20, indicating a potential upside of 130.98%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than EIKN.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 1 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.83EIKN 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has preferable valuation & earnings, RARE or EIKN? EIKN has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$673M3.42-$575M-$6.11N/AEIKNN/AN/AN/AN/AN/A Is RARE or EIKN more profitable? EIKN has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. EIKN's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-91.03% -1,024.42% -45.78% EIKN N/A N/A N/A Does the media refer more to RARE or EIKN? In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than EIKN. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 4 mentions for EIKN. Ultragenyx Pharmaceutical's average media sentiment score of 1.04 beat EIKN's score of 0.99 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive EIKN 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in RARE or EIKN? 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryUltragenyx Pharmaceutical beats EIKN on 9 of the 12 factors compared between the two stocks.How does EIKN compare to Kailera Therapeutics?EIKN (NASDAQ:EIKN) and Kailera Therapeutics (NASDAQ:KLRA) are both manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Does the media prefer EIKN or KLRA? In the previous week, EIKN had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 4 mentions for EIKN and 2 mentions for Kailera Therapeutics. EIKN's average media sentiment score of 0.99 beat Kailera Therapeutics' score of 0.00 indicating that EIKN is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment EIKN 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend EIKN or KLRA? EIKN presently has a consensus price target of $25.20, indicating a potential upside of 130.98%. Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 101.94%. Given EIKN's higher possible upside, equities analysts plainly believe EIKN is more favorable than Kailera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EIKN 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Kailera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, EIKN or KLRA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEIKNN/AN/AN/AN/AN/AKailera TherapeuticsN/AN/AN/AN/AN/A Is EIKN or KLRA more profitable? Company Net Margins Return on Equity Return on Assets EIKNN/A N/A N/A Kailera Therapeutics N/A N/A N/A SummaryEIKN beats Kailera Therapeutics on 3 of the 5 factors compared between the two stocks.How does EIKN compare to Immunome?Immunome (NASDAQ:IMNM) and EIKN (NASDAQ:EIKN) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability. Do insiders and institutionals believe in IMNM or EIKN? 44.6% of Immunome shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, IMNM or EIKN? EIKN has lower revenue, but higher earnings than Immunome. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$6.94M353.46-$212.39M-$2.38N/AEIKNN/AN/AN/AN/AN/A Is IMNM or EIKN more profitable? EIKN's return on equity of 0.00% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets ImmunomeN/A -51.15% -47.32% EIKN N/A N/A N/A Do analysts rate IMNM or EIKN? Immunome presently has a consensus target price of $32.82, suggesting a potential upside of 51.52%. EIKN has a consensus target price of $25.20, suggesting a potential upside of 130.98%. Given EIKN's higher possible upside, analysts plainly believe EIKN is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92EIKN 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Does the media refer more to IMNM or EIKN? In the previous week, Immunome and Immunome both had 4 articles in the media. Immunome's average media sentiment score of 1.23 beat EIKN's score of 0.99 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive EIKN 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryImmunome beats EIKN on 7 of the 10 factors compared between the two stocks.How does EIKN compare to Nanobiotix?Nanobiotix (NASDAQ:NBTX) and EIKN (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Does the media favor NBTX or EIKN? In the previous week, Nanobiotix had 11 more articles in the media than EIKN. MarketBeat recorded 15 mentions for Nanobiotix and 4 mentions for EIKN. EIKN's average media sentiment score of 0.99 beat Nanobiotix's score of 0.07 indicating that EIKN is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral EIKN 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, NBTX or EIKN? EIKN has lower revenue, but higher earnings than Nanobiotix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix$36.87M53.97-$27.11MN/AN/AEIKNN/AN/AN/AN/AN/A Do insiders & institutionals hold more shares of NBTX or EIKN? 38.8% of Nanobiotix shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is NBTX or EIKN more profitable? Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A EIKN N/A N/A N/A Do analysts prefer NBTX or EIKN? Nanobiotix presently has a consensus price target of $26.67, suggesting a potential downside of 34.98%. EIKN has a consensus price target of $25.20, suggesting a potential upside of 130.98%. Given EIKN's stronger consensus rating and higher possible upside, analysts plainly believe EIKN is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50EIKN 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryNanobiotix and EIKN tied by winning 4 of the 8 factors compared between the two stocks.How does EIKN compare to Mineralys Therapeutics?EIKN (NASDAQ:EIKN) and Mineralys Therapeutics (NASDAQ:MLYS) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Do analysts prefer EIKN or MLYS? EIKN presently has a consensus price target of $25.20, indicating a potential upside of 130.98%. Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 65.27%. Given EIKN's higher possible upside, equities analysts clearly believe EIKN is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EIKN 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Mineralys Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Which has better valuation & earnings, EIKN or MLYS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEIKNN/AN/AN/AN/AN/AMineralys TherapeuticsN/AN/A-$154.65M-$2.05N/A Is EIKN or MLYS more profitable? EIKN's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets EIKNN/A N/A N/A Mineralys Therapeutics N/A -27.92%-26.98% Do insiders and institutionals believe in EIKN or MLYS? 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor EIKN or MLYS? In the previous week, Mineralys Therapeutics had 6 more articles in the media than EIKN. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 4 mentions for EIKN. Mineralys Therapeutics' average media sentiment score of 1.03 beat EIKN's score of 0.99 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment EIKN 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMineralys Therapeutics beats EIKN on 6 of the 9 factors compared between the two stocks. Get EIKN News Delivered to You Automatically Sign up to receive the latest news and ratings for EIKN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EIKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EIKN vs. The Competition ExportMetricEIKNBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$590.66M$431.65M$4.26B$12.34BDividend YieldN/AN/A5.93%5.28%P/E RatioN/AN/A21.9025.65Price / SalesN/A326.53180.5586.28Price / CashN/AN/A55.6856.67Price / BookN/A3.2534.857.14Net IncomeN/A-$81.71M$112.32M$335.98M7 Day Performance-7.15%0.41%2.55%3.56%1 Month Performance13.06%2.02%3.54%2.54%1 Year PerformanceN/AN/A15.79%35.05% EIKN Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EIKNEIKNN/A$10.91flat$25.20+131.0%N/A$590.66MN/AN/A384Gap UpRAREUltragenyx Pharmaceutical3.3103 of 5 stars$23.83-1.5%$60.41+153.5%-34.4%$2.36B$673MN/A1,371KLRAKailera Therapeutics4.5595 of 5 stars$19.00-2.8%$42.75+125.0%N/A$2.35BN/AN/A145Quiet Period ExpirationIMNMImmunome3.4533 of 5 stars$19.58-1.6%$32.82+67.6%+155.1%$2.23B$6.94MN/A40Positive NewsGap UpNBTXNanobiotix2.4433 of 5 stars$45.94-7.2%$26.67-42.0%+979.5%$2.23B$36.87MN/A100Gap Up Related Companies and Tools Related Companies Ultragenyx Pharmaceutical Competitors Kailera Therapeutics Competitors Immunome Competitors Nanobiotix Competitors Mineralys Therapeutics Competitors Kodiak Sciences Competitors HUTCHMED Competitors Zai Lab Competitors Tyra Biosciences Competitors Adaptive Biotechnologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EIKN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EIKN Please log in to your account or sign up in order to add this asset to your watchlist. Share EIKN With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
